<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588857</url>
  </required_header>
  <id_info>
    <org_study_id>DEXAPAE</org_study_id>
    <nct_id>NCT04588857</nct_id>
  </id_info>
  <brief_title>Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia</brief_title>
  <official_title>Randomized Double-blind Placebo-controlled Trial on the Efficacy of a Single Dose Dexamethasone in Reducing the Postembolization Syndrome in Men Undergoing Prostatic Artery Embolization for Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms (LUTS)&#xD;
      in men. One fourth of men older than 70 have moderate to severe LUTS that impair their&#xD;
      quality of life (QOL). Prostatic artery embolization (PAE) is a new minimally invasive&#xD;
      technique proven effective in reducing LUTS comparable to the mainstay treatment - the&#xD;
      transurethral resection of the prostate (TURP).&#xD;
&#xD;
      The most common side effect of PAE is a collection of inflammation-related symptoms known as&#xD;
      the postembolization syndrome (PES). The symptoms include pelvic pain, fever, nausea, and&#xD;
      transient worsening of LUTS (painful and difficult urination). PES is a self-limiting&#xD;
      condition that is treated symptomatically with painkillers and antipyretics. However, PES can&#xD;
      be so severe that the patients experience high fever, shivers, dysuria and urgency mimicking&#xD;
      a septicemia from the urinary tract. It is a clinical challenge to avoid exposure to&#xD;
      unnecessary antibiotics treatment in those situations. A subset of patients may need&#xD;
      admission to the hospital for observation, especially in case of fever. Usually, PES resolves&#xD;
      within a week after PAE. Steroids have been successfully used to reduce the incidence and&#xD;
      severity of PES after a number of procedures in interventional radiology. The investigators&#xD;
      postulate that steroids can have a similar effect in reducing PES after PAE. In this study,&#xD;
      the efficacy of single high dose postprocedural dexamethasone (DEXA) administration in&#xD;
      reducing PES after PAE will be evaluated, compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body temperature</measure>
    <time_frame>Measured by participant on Day 2 following PAE,</time_frame>
    <description>Mean rectal body temperature, measured in degrees Celsius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprocedural pain</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Mean postprocedural pain measured on Brief Pain Inventory Short Form (BPI-SF), score on a 0-10 scale, higher score indicates higher level of pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postprocedural quality of life</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Mean postprocedural quality of life measured on BPI-SF, score on a 0-10 scale, higher score indicates lower quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response markers</measure>
    <time_frame>Measured at baseline and 2 days following PAE</time_frame>
    <description>C-reactive protein, measured in mg/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA)</measure>
    <time_frame>Measured at baseline, 2 days, 1 month, 3 months, and 6 months following PAE</time_frame>
    <description>PSA, measured in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for postprocedural medication</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Use of analgesics, antipyretics and antiemetics (frequency and dosage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital admission</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LUTS severity</measure>
    <time_frame>Measured at baseline, 2 days, 5 days, 1 month, 3 months, and 6 months following PAE</time_frame>
    <description>Measured on International Prostate Symptom Score (IPSS) questionnaire, each answer is scored from 0 to 5 for a maximum score of 35 points, higher score indicates more pronounced symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile function</measure>
    <time_frame>Measured at baseline, 1 month, 3 months, and 6 months following PAE</time_frame>
    <description>Measured on International Index of Erectile Function (IIEF-5) questionnaire, each answer is scored from 1 to 5 for a maximum score of 25 points, higher score indicates more pronounced symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate volume</measure>
    <time_frame>Measured at baseline, 3 and 6 months following PAE</time_frame>
    <description>Measured on transrectal US, in ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak urinary flow rate (Qmax)</measure>
    <time_frame>Measured at baseline, 3 and 6 months following PAE</time_frame>
    <description>Qmax, measured in ml/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean urinary flow rate (Qmean)</measure>
    <time_frame>Measured at baseline, 3 and 6 months following PAE</time_frame>
    <description>Qmean, measured in ml/s</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual urine</measure>
    <time_frame>Measured at baseline, 3 and 6 months following PAE</time_frame>
    <description>Residual urine, measured in ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary tract infections</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of urinary tract infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute urinary retention</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of acute urinary retention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of PAE</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of side effects of PAE (PES excluded)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dysuria</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of dysuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea and vomiting</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Incidence of nausea and vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose</measure>
    <time_frame>During the first 5 days following PAE</time_frame>
    <description>Self-measured fasting blood glucose in mmol/l, only in patients with diabetes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Active drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexamethasone 24 mg i.v., single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline i.v., single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>The participants in the experimental group will receive a single 24 mg intravenous dose of dexamethasone immediately prior to PAE.</description>
    <arm_group_label>Active drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>The participants in the placebo group will receive 6 ml of saline i.v. immediately prior to PAE.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of LUTS secondary to BPH refractory to/contraindicated for medical treatment&#xD;
             or not patient preference&#xD;
&#xD;
          -  Moderate to severe urinary symptoms on IPSS (IPSS score 8 or over)&#xD;
&#xD;
          -  Qmax &lt;=15ml/sec, based on flowmetry&#xD;
&#xD;
          -  Unsuitable for TURP or refuses surgery&#xD;
&#xD;
          -  Ability to understand and the willingness to sign an informed consent&#xD;
&#xD;
          -  Prostate volume &gt; 80 milliliters&#xD;
&#xD;
          -  Men with low-risk prostate cancer (T1c, Gleason score &lt;=6 on a maximum of 3 biopsies)&#xD;
             who have LUTS due to a large BPH component are eligible&#xD;
&#xD;
          -  Indwelling or intermittent catheter is allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of bladder cancer&#xD;
&#xD;
          -  Previous pelvic radiation for cancer treatment&#xD;
&#xD;
          -  Current bladder stones&#xD;
&#xD;
          -  Significant bladder diverticula&#xD;
&#xD;
          -  Current urethral strictures or bladder neck contracture&#xD;
&#xD;
          -  Neurologic conditions such as multiple sclerosis, Parkinson's disease and other&#xD;
             neurological diseases known to affect bladder function&#xD;
&#xD;
          -  Neurogenic bladder without obstruction&#xD;
&#xD;
          -  Active urinary tract infection at the time of intervention unless in case of regular&#xD;
             catheter dependence and thought to represent colonization&#xD;
&#xD;
          -  Documented bacterial prostatitis in the last year&#xD;
&#xD;
          -  Severe atheromatous disease or other pathology preventing catheter-based intervention&#xD;
             (as rated on CT angiography by an interventional radiologist)&#xD;
&#xD;
          -  Allergy to iodinated contrast media&#xD;
&#xD;
          -  Renal failure (eGFR &lt; 30ml/min)&#xD;
&#xD;
          -  High bleeding risk (spontaneous INR &gt; 1.6)&#xD;
&#xD;
          -  Contraindication to conscious sedation (if requested by participant)&#xD;
&#xD;
          -  Allergy to dexamethasone&#xD;
&#xD;
          -  Positive HIV, hepatitis B or C&#xD;
&#xD;
          -  Immunological disease (except topically treated skin or respiratory diseases)&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Active peptic or duodenal ulcer&#xD;
&#xD;
          -  Systemic fungal infections&#xD;
&#xD;
          -  Immunosuppressive treatment (systemic)&#xD;
&#xD;
          -  Current treatment of cancer (except low risk prostate cancer)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars B Lonn, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin A RÃ¸der, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Petra Svarc, MD</last_name>
    <phone>+4591870618</phone>
    <email>petra.svarc@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Svarc, MD</last_name>
      <phone>91870618</phone>
      <email>petra.svarc@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 2, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Petra Svarc, MD</investigator_full_name>
    <investigator_title>PhD student</investigator_title>
  </responsible_party>
  <keyword>Prostatic artery embolization</keyword>
  <keyword>Benign prostatic hyperplasia</keyword>
  <keyword>Postembolization syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results of this trial will be submitted for publication in a peer reviewed journal, in addition to reports at appropriate specialist conferences. The results of the trial will be disseminated regardless of the direction of effect.&#xD;
The investigators intend to share de-identified individual participant data that underlie the results reported in the published article following reasonable requests to the principal investigator, and if in accordance with Danish law.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available beginning 9 months and ending 36 months after article publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be made available to qualified scientific researchers who provide a methodologically sounds proposal following reasonable requests to the principal investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

